Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menjugate booster B-cell kinetics study in previously primed toddlers
2006-000732-28Phase 4Completed
- Sponsor
- Chiron Corporation
- Start
- Feb 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease, sponsored by Chiron Corporation. Primary endpoint: Persistence of meningococcal C memory B cells at least one year after primary immunisation. Started Feb 2006; status: completed.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2006-000732-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000732-28.